In its second announcement of the year, ReNeuron, the Surrey based stem cell developer, has announced new data on the stability of the company's CTX stem cell line.
Researchers from University College London are due to tell a conference in San Diego that the results show "CTX cells retained their morphology and growth characteristics when exposed to the ... stresses that could be experienced during large-scale manufacture".
Dr. John Sinden, Chief Scientific Officer of ReNeuron, commented:
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"These new research results demonstrate the robust nature of ReNeuron's CTX cell line when subjected to manufacturing scale-up stresses and thus the potential of this cell line to form the basis of a cell-based therapeutic product for wide-scale clinical application."
The CTX cell line is currently in phase 1 clinical development as a therapy for patients disabled by strokes.
ReNeuron shares have dropped 18% in the past 12 months, but are up on the week after the company announced positive study data on January 3rd for its ReN001 stem cell therapy for disabled stroke patients.
Despite the positive announcement today, the shares eased back a tenth of a penny to 5.35p in the morning session.
bs
-
Lloyds axes foreign currency fees for Club Lloyds customersClub Lloyds customers will be able to withdraw their money abroad without incurring any extra fees
-
How to invest during stagflationTrump’s tariffs look poised to push the global economy into a period of stagflation. We look at how to ensure your investments can survive a global slowdown.
